Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.

Purpose: The treatment of chronic myeloid leukemia (CML) has improved considerably since the introduction of the tyrosine kinase inhibitor (TKI) imatinib in 2001 and the approval of second-generation TKIs (dasatinib and nilotinib) beginning in 2006.The objective of this study was to explore treatment patterns of TKI therapy (adherence, duration, and switching) among patients with CML in the United States, following the availability of second-generation TKIs.

Methods: This study used US health plan claims data from January 1, 2007, through December 31, 2011.

The safety and efficacy of celecoxib in children with familial adenomatous polyposis.

Objectives: Celecoxib is approved as an adjunctive chemopreventive agent in adults with familial adenomatous polyposis (FAP). Its safety and efficacy for colorectal polyps in children is unknown. We evaluated the short-term (3 months) safety and preliminary efficacy of celecoxib in children with FAP.

The emergence of resistance to amikacin in Serratia marcescens isolates from patients with nosocomial infection.

Administration of either amikacin (1985) or gentamicin (1984, 1986-1991) as first-choice aminoglycoside did not decrease the high incidence of amikacin-resistant Serratia marcescens (ARSm) isolates responsible for nosocomial infections at the J.A. Fernández Hospital of Buenos Aires (42% in 1984, 31% in 1985 and 41% in 1987, differences not significant).

Survey of the levels of antimicrobial resistance in Argentina: WHONET program--1991 to 1994.

The World Health Organization has implemented an international program of antibiotic resistance survey, called WHONET, with the participation of 121 laboratories from 41 countries around the world. Argentina joined WHONET program in 1989. Five hospitals from Buenos Aires are taking part, under the coordination of the National Institute of Microbiology 'Dr.

Non-typhoid Salmonella spp. resistant to cefotaxime.

beta-Lactamases with pIs of 5.4 and 8.1 were detected by hydrolysis of ampicillin and ceftriaxone respectively among cefotaxime resistant serovars of Salmonella spp.

Sequences related to Tn1331 associated with multiple antimicrobial resistance in different Salmonella serovars.

Serovars of Salmonella resistant to ampicillin, third-generation cephalosporins and aminoglycosides but sensitive to chloramphenicol, cefoxitin and ceftibuten emerged in one pediatric hospital of Buenos Aires. All isolates expressed AAC(6')-I and AAC(3)-V enzyme activities, making them resistant to all aminoglycosides marketed in Argentina by the time this investigation was performed. The cefotaxime resistance marker, the AAC(3)-V enzyme activity and Tn1331-related sequences were associated with plasmid DNAs from different Salmonella serovars.

Ceftibuten and trimethoprim-sulfamethoxazole for treatment of Shigella and enteroinvasive Escherichia coli disease.

In a prospective randomized study at two clinical sites, ceftibuten was compared with trimethoprim-sulfamethoxazole (TMP-SMX), both given orally for a period of 5 days, for the treatment of dysentery. Twenty-two children were found to have bacillary dysentery caused by Shigella and/or enteroinvasive Escherichia coli. All organisms isolated were susceptible to ceftibuten; 6 of 20 Shigella strains and 4 of 5 enteroinvasive E.

Evidence of infection with organisms producing Shiga-like toxins in household contacts of children with the hemolytic uremic syndrome.

We conducted a prospective study in 87 household contacts of 51 children with hemolytic uremic syndrome to determine the frequency of infection with Shiga-like toxin-producing bacteria. Gastrointestinal tract symptoms occurred in only 1 of 87 contacts. Free fecal toxin was detected in 25 of 64 (39%) of the household members.

Hemolytic uremic syndrome and diarrhea in Argentine children: the role of Shiga-like toxins.

Shiga-like toxin-producing Escherichia coli have been associated with hemorrhagic colitis and the hemolytic uremic syndrome (HUS). Because Argentina has the highest reported frequency of HUS in the world, Argentine children were prospectively studied during the HUS seasons for evidence of Shiga-like toxin-related diseases. On the basis of serology, fecal cytotoxin neutralization, stool cultures, and DNA hybridization of colony lysates, most children with HUS had evidence of infection with Shiga-like toxin-producing organisms.

Molecular cloning of amikacin resistance determinants from a Klebsiella pneumoniae plasmid.

A multiresistant Klebsiella pneumoniae strain, JHCK1, harbored several plasmids. One of these, plasmid pJHCMW1, carried determinants for resistance to amikacin in addition to kanamycin, tobramycin, and ampicillin. The amikacin resistance determinant(s) was cloned and studied by restriction mapping, insertion, and deletion analysis.

Plasmid-encoded amikacin resistance in multiresistant strains of Klebsiella pneumoniae isolated from neonates with meningitis.

Two multiresistant Klebsiella pneumoniae strains isolated from cerebrospinal fluid of human neonates were analyzed for their plasmid content. Two of the plasmids harbored by these strains, pJHCMW1 (11 kilobase pairs) and pJHCMW4 (75 kilobase pairs), carried genetic determinants for amikacin resistance. These plasmids also encoded resistance to kanamycin, tobramycin, and ampicillin which could be transferred to Escherichia coli by conjugation.